Olema Pharmaceuticals (OLMA) Stock Forecast, Price Target & Predictions
OLMA Stock Forecast
Olema Pharmaceuticals stock forecast is as follows: an average price target of $28.50 (represents a 244.20% upside from OLMA’s last price of $8.28) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
OLMA Price Target
OLMA Analyst Ratings
Buy
Olema Pharmaceuticals Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Oct 24, 2024 | Richard Law | Goldman Sachs | $27.00 | $11.91 | 126.70% | 226.09% |
May 16, 2024 | Emily Bodnar | H.C. Wainwright | $30.00 | $9.85 | 204.57% | 262.32% |
Apr 02, 2024 | Richard Law | Goldman Sachs | $24.00 | $10.89 | 120.39% | 189.86% |
10
Olema Pharmaceuticals Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | 1 | 1 | 3 |
Avg Price Target | $27.00 | $27.00 | $27.00 |
Last Closing Price | $8.28 | $8.28 | $8.28 |
Upside/Downside | 226.09% | 226.09% | 226.09% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Oct 24, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Oct 24, 2024 | Goldman Sachs | Buy | Buy | Hold |
Jun 04, 2024 | Oppenheimer | Outperform | Outperform | Hold |
May 16, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Apr 02, 2024 | Goldman Sachs | - | Buy | Initialise |
Jun 09, 2022 | H.C. Wainwright | - | Buy | Upgrade |
10
Olema Pharmaceuticals Financial Forecast
Olema Pharmaceuticals Revenue Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
# Analysts | - | - | - | - | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Forecast
Olema Pharmaceuticals EBITDA Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Forecast
Olema Pharmaceuticals Net Income Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - | - | - | - | - |
Net Income | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | $-39.65M | $-36.19M | $-34.39M | $-41.97M | $-42.09M | $-37.22M | $-36.46M | $-35.31M | $-36.42M | $-32.70M | $-30.57M |
High Forecast | $-39.65M | $-36.19M | $-34.39M | $-41.97M | $-42.09M | $-37.22M | $-36.46M | $-35.31M | $163.88M | $-32.70M | $-30.57M |
Low Forecast | $-39.65M | $-36.19M | $-34.39M | $-41.97M | $-42.09M | $-37.22M | $-36.46M | $-35.31M | $-962.77M | $-32.70M | $-30.57M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Forecast
Olema Pharmaceuticals SG&A Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - | - | - | - | - |
SG&A | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Forecast
Olema Pharmaceuticals EPS Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - | - | - | - | - |
EPS | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | $-0.69 | $-0.63 | $-0.60 | $-0.73 | $-0.73 | $-0.65 | $-0.64 | $-0.62 | $-0.64 | $-0.57 | $-0.54 |
High Forecast | $-0.69 | $-0.63 | $-0.60 | $-0.73 | $-0.73 | $-0.65 | $-0.64 | $-0.62 | $2.86 | $-0.57 | $-0.54 |
Low Forecast | $-0.69 | $-0.63 | $-0.60 | $-0.73 | $-0.73 | $-0.65 | $-0.64 | $-0.62 | $-16.81 | $-0.57 | $-0.54 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Forecast
Olema Pharmaceuticals Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
ZNTL | Zentalis Pharmaceuticals | $3.13 | $21.86 | 598.40% | Buy |
ANTX | AN2 Therapeutics | $1.30 | $8.75 | 573.08% | Buy |
PEPG | PepGen | $4.40 | $29.50 | 570.45% | Buy |
LIFE | aTyr Pharma | $1.90 | $11.00 | 478.95% | Buy |
MOLN | Molecular Partners | $5.20 | $29.00 | 457.69% | Buy |
OLMA | Olema Pharmaceuticals | $8.28 | $28.50 | 244.20% | Buy |
FENC | Fennec Pharmaceuticals | $4.64 | $15.75 | 239.44% | Buy |
LRMR | Larimar Therapeutics | $6.08 | $20.33 | 234.38% | Buy |
SANA | Sana Bio | $2.53 | $8.00 | 216.21% | Buy |
CGEM | Cullinan Oncology | $12.58 | $31.50 | 150.40% | Buy |
ERAS | Erasca | $2.64 | $6.50 | 146.21% | Buy |
MLYS | Mineralys Therapeutics | $12.60 | $30.00 | 138.10% | Buy |
PHVS | Pharvaris | $20.50 | $39.67 | 93.51% | Buy |
DSGN | Design Therapeutics | $5.48 | $9.67 | 76.46% | Buy |
CNTA | Centessa Pharmaceuticals | $16.74 | $23.25 | 38.89% | Buy |
IRON | Disc Medicine | $62.55 | $72.50 | 15.91% | Buy |
GRCL | Gracell Bio | $10.25 | $6.00 | -41.46% | Buy |